ARPA-H announced THRIVE, a program committing up to $160 million to develop custom gene editing treatments for a range of rare diseases. The effort backs seven teams, with deadlines tied to starting clinical trials by year three. The plan targets rapid translation of gene editing beyond single-asset development, emphasizing a repeated build-and-test cycle across multiple organ systems. For the sector, the announcement provides a new non-dilutive path for platformized gene editing programs and reinforces the U.S. push to accelerate first-in-human execution timelines.